Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 805

1.

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B.

Eur J Cancer. 2019 Jun 15;116:207-215. doi: 10.1016/j.ejca.2019.05.015. [Epub ahead of print]

PMID:
31212163
2.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C.

Eur J Cancer. 2019 Jun 11;116:148-157. doi: 10.1016/j.ejca.2019.05.020. [Epub ahead of print]

PMID:
31200321
3.

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib.

Lewis K, Hauschild A, Larkin J, Ribas A, Flaherty KT, McArthur GA, Dréno B, McKenna E, Zhu Q, Mun Y, Ascierto PA.

Eur J Cancer. 2019 Jun 4;116:45-55. doi: 10.1016/j.ejca.2019.05.002. [Epub ahead of print]

PMID:
31173962
4.

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.

Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR.

Oncologist. 2019 Jun 6. pii: theoncologist.2018-0749. doi: 10.1634/theoncologist.2018-0749. [Epub ahead of print]

PMID:
31171735
5.

Activation of the unfolded protein response in high glucose treated endothelial cells is mediated by methylglyoxal.

Irshad Z, Xue M, Ashour A, Larkin JR, Thornalley PJ, Rabbani N.

Sci Rep. 2019 May 27;9(1):7889. doi: 10.1038/s41598-019-44358-1.

6.

To Browse, Click "Search".

Larkin J.

Scott Med J. 2019 May;64(2):41. doi: 10.1177/0036933019848950. No abstract available.

PMID:
31119981
7.

Microfluidic droplet liquid reactors for active pharmaceutical ingredient crystallization by diffusion controlled solvent extraction.

Tona RM, McDonald TAO, Akhavein N, Larkin JD, Lai D.

Lab Chip. 2019 Jun 11;19(12):2127-2137. doi: 10.1039/c9lc00204a.

PMID:
31114833
8.

Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer.

Sharma J, Larkin J 3rd.

Front Pharmacol. 2019 Apr 11;10:324. doi: 10.3389/fphar.2019.00324. eCollection 2019. Review.

9.

An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.

O'Reilly A, Hughes P, Mann J, Lai Z, Teh JJ, Mclean E, Edmonds K, Lingard K, Chauhan D, Lynch J, Au L, Ludlow A, Pattison N, Wiseman T, Turajlic S, Gore M, Larkin J, Husson O.

Support Care Cancer. 2019 May 14. doi: 10.1007/s00520-019-04818-w. [Epub ahead of print]

PMID:
31089820
10.

The Late Effects of Radiation Therapy on Skeletal Muscle Morphology and Progenitor Cell Content are Influenced by Diet-Induced Obesity and Exercise Training in Male Mice.

D'Souza D, Roubos S, Larkin J, Lloyd J, Emmons R, Chen H, De Lisio M.

Sci Rep. 2019 Apr 30;9(1):6691. doi: 10.1038/s41598-019-43204-8.

11.

Current and emerging systemic therapies for cutaneous metastatic melanoma.

Mason R, Au L, Ingles Garces A, Larkin J.

Expert Opin Pharmacother. 2019 Jun;20(9):1135-1152. doi: 10.1080/14656566.2019.1601700. Epub 2019 Apr 26.

PMID:
31025594
12.

Reply to E. Hindié and K.R. Hess.

Long GV, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Hauschild A.

J Clin Oncol. 2019 May 20;37(15):1356-1358. doi: 10.1200/JCO.19.00004. Epub 2019 Apr 2. No abstract available.

PMID:
30939092
13.

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV.

Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27.

PMID:
30928620
14.

Modeling Boronic Acid Based Fluorescent Saccharide Sensors: Computational Investigation of d-Fructose Binding to Dimethylaminomethylphenylboronic Acid.

Kearns FL, Robart C, Kemp MT, Vankayala SL, Chapin BM, Anslyn EV, Woodcock HL, Larkin JD.

J Chem Inf Model. 2019 May 28;59(5):2150-2158. doi: 10.1021/acs.jcim.8b00987. Epub 2019 Apr 22.

PMID:
30908030
15.

Design and methodology of the impact of HemoDiaFIlTration on physical activity and self-reported outcomes: a randomized controlled trial (HDFIT trial) in Brazil.

Pecoits-Filho R, Larkin JW, Poli-de-Figueiredo CE, Cuvello Neto AL, Barra AB, Canhada S, de Campos LG, Woehl J, Gonçalves PB, Han H, de Moraes TP, Raimann JG, Canziani MEF; HDFIT Study Investigators.

BMC Nephrol. 2019 Mar 20;20(1):98. doi: 10.1186/s12882-019-1247-8.

16.

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.

Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dréno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A.

Clin Cancer Res. 2019 Jun 1;25(11):3239-3246. doi: 10.1158/1078-0432.CCR-18-0720. Epub 2019 Mar 1.

PMID:
30824584
17.

Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma.

Hayes AJ, Moskovic E, O'Meara K, Smith HG, Pope RJE, Larkin J, Thomas JM.

Br J Surg. 2019 May;106(6):729-734. doi: 10.1002/bjs.11112. Epub 2019 Feb 28.

PMID:
30816996
18.

Editorial.

Larkin J.

Scott Med J. 2019 Feb;64(1):1. doi: 10.1177/0036933019830890. No abstract available.

PMID:
30782108
19.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK.

N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.

PMID:
30779531
20.

Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.

Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bahl A, Fife K, Webb A, Crabb SJ, Geldart T, Hill R, Dunlop J, McLaren D, Ackerman C, Wimalasingham A, Beltran L, Nathan P, Powles T.

Eur Urol Focus. 2019 Feb 6. pii: S2405-4569(19)30010-0. doi: 10.1016/j.euf.2019.01.010. [Epub ahead of print]

PMID:
30738795
21.

The Impact of Indigenous Youth Sharing Digital Stories About HIV Activism.

Flicker S, Wilson C; Native Youth Sexual Health Network, Monchalin R, Restoule JP, Mitchell C, Larkin J, Prentice T, Jackson R, Oliver V.

Health Promot Pract. 2019 Feb 6:1524839918822268. doi: 10.1177/1524839918822268. [Epub ahead of print]

PMID:
30724108
22.

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A Jr, Mookerjee B, Schadendorf D.

Eur J Cancer. 2019 Mar;109:61-69. doi: 10.1016/j.ejca.2018.12.015. Epub 2019 Jan 25.

PMID:
30690294
23.

Tumor pH and Protein Concentration Contribute to the Signal of Amide Proton Transfer Magnetic Resonance Imaging.

Ray KJ, Simard MA, Larkin JR, Coates J, Kinchesh P, Smart SC, Higgins GS, Chappell MA, Sibson NR.

Cancer Res. 2019 Apr 1;79(7):1343-1352. doi: 10.1158/0008-5472.CAN-18-2168. Epub 2019 Jan 24.

PMID:
30679178
24.

Colonic stenting as a bridge to surgery in malignant large bowel obstruction: oncological outcomes.

Donlon NE, Kelly ME, Narouz F, McCormick PH, Larkin JO, Mehigan BJ.

Int J Colorectal Dis. 2019 Apr;34(4):613-619. doi: 10.1007/s00384-019-03239-9. Epub 2019 Jan 16.

PMID:
30652215
25.

Preflight Contingency Planning Approach for Fixed Wing UAVs with Engine Failure in the Presence of Winds.

Ayhan B, Kwan C, Budavari B, Larkin J, Gribben D.

Sensors (Basel). 2019 Jan 9;19(2). pii: E227. doi: 10.3390/s19020227.

26.

Longitudinal patterns of health-related quality of life and dialysis modality: a national cohort study.

Eneanya ND, Maddux DW, Reviriego-Mendoza MM, Larkin JW, Usvyat LA, van der Sande FM, Kooman JP, Maddux FW.

BMC Nephrol. 2019 Jan 8;20(1):7. doi: 10.1186/s12882-018-1198-5.

27.

The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study.

Johansson M, Carreras-Torres R, Scelo G, Purdue MP, Mariosa D, Muller DC, Timpson NJ, Haycock PC, Brown KM, Wang Z, Ye Y, Hofmann JN, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Garnier JG, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Radojevic-Skodric S, Ognjanovic S, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Benhamou S, Cancel-Tassin G, Cussenot O, Weiderpass E, Ljungberg B, Tumkur Sitaram R, Häggström C, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Andreotti G, Beane Freeman LE, Koutros S, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Wilson KM, Gaziano JM, Sesso HD, Freedman ND, Parker AS, Eckel-Passow JE, Huang WY, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, Choueiri TK, Lathrop GM, Deleuze JF, Gunter M, McKay JD, Wu X, Houlston RS, Chanock SJ, Relton C, Richards JB, Martin RM, Davey Smith G, Brennan P.

PLoS Med. 2019 Jan 3;16(1):e1002724. doi: 10.1371/journal.pmed.1002724. eCollection 2019 Jan.

28.

Conservation of Neotropical migratory birds in tropical hardwood and oil palm plantations.

Bennett RE, Leuenberger W, Bosarreyes Leja BB, Sagone Cáceres A, Johnson K, Larkin J.

PLoS One. 2018 Dec 31;13(12):e0210293. doi: 10.1371/journal.pone.0210293. eCollection 2018.

29.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C.

Eur J Cancer. 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20.

PMID:
30580112
30.

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.

Proskorovsky I, Benedict A, Negrier S, Bargo D, Sandin R, Ramaswamy K, Desai J, Cappelleri JC, Larkin J.

BMC Cancer. 2018 Dec 19;18(1):1271. doi: 10.1186/s12885-018-5157-0.

31.

Future career intentions of recent GP graduates in Ireland: a trend analysis study.

Pericin I, Mansfield G, Larkin J, Collins C.

BJGP Open. 2018 Apr 21;2(1):bjgpopen18X101409. doi: 10.3399/bjgpopen18X101409. eCollection 2018 Apr.

32.

Young Forest Conservation Incentive Programs: Explaining Re-Enrollment and Post-program Persistence.

Lutter SH, Dayer AA, Larkin JL.

Environ Manage. 2019 Feb;63(2):270-281. doi: 10.1007/s00267-018-1127-1. Epub 2018 Dec 9.

PMID:
30535797
33.

Sensitivity of Multiphase Pseudocontinuous Arterial Spin Labelling (MP pCASL) Magnetic Resonance Imaging for Measuring Brain and Tumour Blood Flow in Mice.

Buck J, Larkin JR, Simard MA, Khrapitchev AA, Chappell MA, Sibson NR.

Contrast Media Mol Imaging. 2018 Nov 7;2018:4580919. doi: 10.1155/2018/4580919. eCollection 2018.

34.

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

Grob JJ, Garbe C, Ascierto P, Larkin J, Dummer R, Schadendorf D.

Lancet Oncol. 2018 Dec;19(12):e720-e725. doi: 10.1016/S1470-2045(18)30596-5. Review.

PMID:
30507438
35.

Social Ecological Factors of Sexual Subjectivity and Contraceptive Use and Access Among Young Women in the Northwest Territories, Canada.

Lys C, Gesink D, Strike C, Larkin J.

J Sex Res. 2018 Nov 30:1-10. doi: 10.1080/00224499.2018.1544604. [Epub ahead of print]

PMID:
30500273
36.

Digitally Delivered Psychological Interventions for Anxiety Disorders: a Comprehensive Review.

Stefanopoulou E, Lewis D, Taylor M, Broscombe J, Larkin J.

Psychiatr Q. 2019 Mar;90(1):197-215. doi: 10.1007/s11126-018-9620-5. Review.

PMID:
30488330
37.

Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes.

Mobasheri A, van Spil WE, Budd E, Uzieliene I, Bernotiene E, Bay-Jensen AC, Larkin J, Levesque MC, Gualillo O, Henrotin Y.

Curr Opin Rheumatol. 2019 Jan;31(1):80-89. doi: 10.1097/BOR.0000000000000567.

PMID:
30461544
38.

A Systematic Review in Support of the National Consensus Project Clinical Practice Guidelines for Quality Palliative Care, Fourth Edition.

Ahluwalia SC, Chen C, Raaen L, Motala A, Walling AM, Chamberlin M, O'Hanlon C, Larkin J, Lorenz K, Akinniranye O, Hempel S.

J Pain Symptom Manage. 2018 Dec;56(6):831-870. doi: 10.1016/j.jpainsymman.2018.09.008. Epub 2018 Oct 31. Review.

PMID:
30391049
39.

A pyrrhic valedictory?

Larkin J.

Scott Med J. 2018 Nov 1:36933018811242. doi: 10.1177/0036933018811242. [Epub ahead of print] No abstract available.

PMID:
30384808
40.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD.

Lancet Oncol. 2018 Nov;19(11):1480-1492. doi: 10.1016/S1470-2045(18)30700-9. Epub 2018 Oct 22. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668. Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
30361170
41.

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV.

J Clin Oncol. 2018 Oct 22:JCO1801219. doi: 10.1200/JCO.18.01219. [Epub ahead of print]

42.

Tract dilation to salvage failing buttonholes in arteriovenous dialysis fistulae.

Barzel E, Larkin JW, Marcus A, Reviriego-Mendoza MM, Usvyat LA, Sor M, Maddux FW.

J Vasc Access. 2019 May;20(3):290-300. doi: 10.1177/1129729818804996. Epub 2018 Oct 14.

PMID:
30319008
43.

13C Pyruvate Transport Across the Blood-Brain Barrier in Preclinical Hyperpolarised MRI.

Miller JJ, Grist JT, Serres S, Larkin JR, Lau AZ, Ray K, Fisher KR, Hansen E, Tougaard RS, Nielsen PM, Lindhardt J, Laustsen C, Gallagher FA, Tyler DJ, Sibson N.

Sci Rep. 2018 Oct 10;8(1):15082. doi: 10.1038/s41598-018-33363-5.

44.

Management of Anesthesia and Delivery in Women With Chiari I Malformations.

Waters JFR, OʼNeal MA, Pilato M, Waters S, Larkin JC, Waters JH.

Obstet Gynecol. 2018 Nov;132(5):1180-1184. doi: 10.1097/AOG.0000000000002943.

PMID:
30303901
45.

Impairment of trophoblast survival and differentiation by LXR ligands is prevented by cholesterol but not ABCA1 silencing.

Harmon CM, McGonigal S, Larkin JC.

Placenta. 2018 Sep;69:50-56. doi: 10.1016/j.placenta.2018.07.003. Epub 2018 Jul 10.

PMID:
30213484
46.

The impact of effective systemic therapies on surgery for stage IV melanoma.

Smith MJF, Smith HG, Joshi K, Gore M, Strauss DC, Hayes AJ, Larkin J.

Eur J Cancer. 2018 Nov;103:24-31. doi: 10.1016/j.ejca.2018.08.008. Epub 2018 Sep 7.

PMID:
30196107
47.

Immune checkpoint inhibitors and cardiovascular toxicity.

Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J.

Lancet Oncol. 2018 Sep;19(9):e447-e458. doi: 10.1016/S1470-2045(18)30457-1. Review.

48.

Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?

Au L, O'Reilly A, Larkin J.

Melanoma Manag. 2017 Sep;4(3):151-155. doi: 10.2217/mmt-2017-0016. Epub 2017 Aug 2. No abstract available.

49.

Immunotherapy for Melanoma Metastatic to the Brain.

Turajlic S, Larkin J.

N Engl J Med. 2018 Aug 23;379(8):789-790. doi: 10.1056/NEJMe1807752. No abstract available.

PMID:
30134137
50.

Sodium and Potassium Intake: Effects on Chronic Disease Outcomes and Risks [Internet].

Newberry SJ, Chung M, Anderson CAM, Chen C, Fu Z, Tang A, Zhao N, Booth M, Marks J, Hollands S, Motala A, Larkin J, Shanman R, Hempel S.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jun.

Supplemental Content

Loading ...
Support Center